Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a2432fff0eb7f25b

Jump to content

Gareth Sanger

From Wikipedia, the free encyclopedia

Gareth Sanger
Employers
Websitewww.icms.qmul.ac.uk/neurogastro/staff/garethsanger.html Edit this at Wikidata

Gareth J. Sanger (born 1953) is a British pharmacologist.

Sanger was a research fellow at King's College Hospital Medical School from 1977 to 1990.[1] He then spent a period in the pharmacological industry,[1] before being appointed, in 2009, Professor of Neuropharmacology, at Queen Mary University of London.[2]

He has served as editor and reviews editor for the "British Journal of Pharmacology" and as an editorial board member for "Drug Discovery Today".[1]

Together with M Tyers he received the 1998 Pharmaceutical Research and Manufacturers of America (PhRMA) "Discoverer's Award" for their research into 5HT3 receptor/antiemesis, which led to the identification and development of the drug Kytril,[1][2] an antiemetic to treat nausea and vomiting following chemotherapy.

References

[edit]
  1. 1 2 3 4 Daphne Christie; Tilli Tansey, eds. (2007). The Discovery, Use and Impact of Platinum Salts as Chemotherapy Agents for Cancer. Wellcome Witnesses to Contemporary Medicine. History of Modern Biomedicine Research Group. ISBN 978-0-85484-112-7. OL 25554713M. Wikidata Q29581749.
  2. 1 2 "Gareth Sanger". The Conversation. Retrieved 26 June 2017.
[edit]